Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study (NOTICE-HF)

April 9, 2014 updated by: Guidant Corporation

Next Generation INCEPTA ICD and CRT-D Field Following Study: Respiratory Rate Trend Evaluation in Heart Failure (HF) Patients

This study has 2 purposes:

The first purpose of the study is to test a new family of Boston Scientific Implantable Cardioverter Defibrillators ("ICDs") and cardiac resynchronization therapy ICDs ("CRT-Ds") and show how well these new devices work in patients. This new family is called the INCEPTA ICD and the INCEPTA CRT-D.

The second purpose of the study is to collect data from a feature that monitors breathing. It is called the Respiratory Rate Trend (RRT). These data will help to better understand how changes in breathing relate to changes in clinical conditions.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Study Purpose

Study purpose I:

To evaluate and document appropriate clinical performance of the INCEPTA (DR and VR) implantable cardioverter defibrillator (ICD) system and the INCEPTA cardiac resynchronization therapy ICD (CRT-D) system and associated application software.

Study purpose II:

Demonstrate the clinical relevance of chronic ambulatory daily median Respiratory Rate Trend (RRT) in HF patients

Study Device

  • INCEPTA (DR and VR) implantable cardioverter defibrillator (ICD) system (Models F160, F161, F162, F163)
  • INCEPTA cardiac resynchronization therapy ICD (CRT-D) system (Models P162, P163, P165)

Indication ICD / CRT-D Indication according to standard clinical practice

Study Objectives

The study has two primary objectives, linked to the respective study purposes:

For purpose I:

The objective is to collect data on the clinical performance of the INCEPTA ICD and CRT-D devices during standard clinical use at implant, pre-discharge and at a 1-month post-implant. Clinical performance included analysis of pacing thresholds, pacing impedance, sensing thresholds, number of successfully converted VT/VF episodes, induced episodes detection times, spontaneous episodes, wanded telemetry, adverse events (AEs) and product experiences.

For purpose II:

The objective is to show that daily median respiratory rate increases more in patients who experience an HF-event (Group 1) than in patients who do not experience an HF-event (Group 2).

This is a prospective, multi-centre, field following study.

Up to 35 study centers in the International geography will enrol 120 patients.

Study Type

Observational

Enrollment (Actual)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany
        • Deutsches Herzzentrum Berlin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients should be selected from the investigator's general population and be indicated for an ICD or CRT-D implantation.

Description

Inclusion Criteria:

  • Patients who are willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical study;
  • Patients whose age is 18 or above, or of legal age to give informed consent specific to national law
  • Patients indicated for an ICD according to normal clinical practice (for those patients receiving an INCEPTA ICD).

    -As soon as 20 ICD patients are included in the study for purpose I, only NYHA Class III patients will be allowed in the study.

  • New York Heart Association (NYHA) Class III patients indicated for a CRT-D according to normal clinical practice (for those patients receiving an INCEPTA CRT-D).

Exclusion Criteria:

  • Women of childbearing potential who are or might be pregnant at the time of the study (method of assessment upon physician's discretion)
  • Enrolled in any other concurrent study.
  • Inability or refusal to comply with the follow-up schedule
  • Patients that have received routinely scheduled intravenous inotropic therapy as part of their drug regimen within the past 90 days
  • Patients prescribed to positive airway pressure therapy
  • A life expectancy of less than 1 year, per physician discretion
  • Patient in NYHA Class IV during the last 4 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
INCEPTA ICD and CRT-D
ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Performance for Left Ventricular (LV) Sensing Amplitude at Implant for CRT-D Patients
Time Frame: implant
Left Ventricular (LV) Sensed Amplitude results were reported at implant for CRT-D patients.
implant
Clinical Performance at Pre-discharge for LV Sensing Amplitude for CRT-D Patients
Time Frame: pre-discharge
Left Ventricular (LV) Sensed Amplitude results were reported pre-discharge for CRT-D patients.
pre-discharge
Clinical Performance at1-month for Left Ventricular (LV) Sensing Amplitude for CRT-D Patients
Time Frame: 1-month
LV Sensed Amplitude results were reported at 1-month post-implant for CRT-D patients.
1-month
Clinical Performance at Implant for Right Atrium (RA) Sensing Amplitude
Time Frame: implant
RA Sensed Amplitude results were reported for implant for CRT-D and ICD patients
implant
Clinical Performance at Pre-discharge for RA Sensing Amplitude
Time Frame: pre-discharge
RA Sensed Amplitude results were reported at pre-discharge for CRT-D and ICD patients
pre-discharge
Clinical Performance at1-month for RA Sensing Amplitude
Time Frame: 1-month
RA Sensed Amplitude results were reported at 1-month post-implant for CRT-D and ICD patients
1-month
Clinical Performance at Implant for Right Ventricle (RV) Sensing Amplitude
Time Frame: implant
RV Sensed Amplitude results were reported at implant for CRT-D and ICD patients
implant
Clinical Performance at Pre-discharge for Right Ventricle (RV) Sensing Amplitude
Time Frame: pre-discharge
RV Sensed Amplitude results were reported at pre-discharge for CRT-D and ICD patients
pre-discharge
Clinical Performance at1-month for Right Ventricle (RV) Sensing Amplitude
Time Frame: 1month
RV Sensed Amplitude results were reported at 1-month post-implant for CRT-D and ICD patients
1month
Clinical Performance at Implant for LV Pacing Threshold
Time Frame: implant
LV pacing threshold results were reported for CRT-D patients at implant.
implant
Clinical Performance at Pre-discharge for LV Pacing Threshold
Time Frame: pre-discharge
LV pacing threshold results were reported at pre-discharge for CRT-D patients.
pre-discharge
Clinical Performance at1-month for LV Pacing Threshold
Time Frame: 1-month
LV pacing threshold results were reported at 1-month post-implant for CRT-D patients.
1-month
Clinical Performance at Implant for RV Pacing Threshold
Time Frame: implant
RV pacing threshold results were reported at implant
implant
Clinical Performance at Pre-discharge for RV Pacing Threshold
Time Frame: pre-discharge
RV pacing threshold results were reported at pre-discharge
pre-discharge
Clinical Performance at 1-month for RV Pacing Threshold
Time Frame: 1-month
RV pacing threshold results were reported at 1-month post-implant
1-month
Clinical Performance at Implant for RA Pacing Threshold
Time Frame: implant
RA pacing threshold results were reported for implant
implant
Clinical Performance at Pre-discharge for RA Pacing Threshold
Time Frame: pre-discharge
RA pacing threshold results were reported at pre-discharge
pre-discharge
Clinical Performance at 1-month for RA Pacing Threshold
Time Frame: 1-month
RA pacing threshold results were reported at 1-month post-implant
1-month
Clinical Performance at Implant LV Pacing Impedance for CRT-D.
Time Frame: implant
LV pacing impedance results at implant were measured in CRT-D.
implant
Clinical Performance at Pre-discharge for LV Pacing Impedance for CRT-D.
Time Frame: pre-discharge
LV pacing impedance results were reported for pre-discharge visit
pre-discharge
Clinical Performance at 1-month for LV Pacing Impedance for CRT-D.
Time Frame: 1-month
LV pacing impedance results were reported at 1-month post-implant
1-month
Clinical Performance at Implant for RV Pacing Impedance
Time Frame: implant
RV pacing impedance results were reported at implant
implant
Clinical Performance at Pre-discharge for RV Pacing Impedance
Time Frame: pre-discharge
RV pacing impedance results were reported for pre-discharge
pre-discharge
Clinical Performance at 1-month for RV Pacing Impedance
Time Frame: 1-month
RV pacing impedance results were reported at 1-month post-implant
1-month
Clinical Performance at Implant for RA Pacing Impedance
Time Frame: implant
RA pacing impedance results were reported at implant
implant
Clinical Performance at Pre-discharge for RA Pacing Impedance
Time Frame: pre-discharge
RA pacing impedance results were reported at pre-discharge
pre-discharge
Clinical Performance at 1-month for RA Pacing Impedance
Time Frame: 1-month
RA pacing impedance results were reported at 1-month post-implant
1-month
Product Experiences Reported by the Site for All Patients for Study Duration
Time Frame: Overall study results
Product experiences reported may include the shock impedance noise display, problems encountered with the universal serial bus (USB), a program parameter mismatch, reverse mode switches, electrogram (EGM) noise without oversensing, lead connection issues, or customer device feedback.
Overall study results
Induced Ventricular Tachycardia / Ventricular Fibrillation (VT/VF) Episode Successful Conversion Rates at Implant
Time Frame: implant
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
implant
Induced VT/VF Episode Successful Conversion Rates at 1-month
Time Frame: 1-month
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
1-month
Induced VT/VF Episode Successful Conversion Rates at 3-months
Time Frame: 3-month
The % of successful conversions after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. All episodes of induced VT/VF that resolved with successful conversion were counted from the total attempted conversions and reported as the % of successful conversions from those attempted.
3-month
Induced Episode Detection Times at Implant
Time Frame: implant
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
implant
Induced Episode Detection Times at 1-month
Time Frame: 1-month
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
1-month
Induced Episode Detection Times at 3 Months
Time Frame: 3-month
The mean time it took to complete a successful conversion after inducing a VT/VF episode was analyzed for available data from CRT and ICD group patients. The time was recorded (in seconds) for the time duration that was required to successfully convert the patient after inducing VT/VF.
3-month
Spontaneous Episode Conversion Success Rate at 3 Months
Time Frame: 3-month
Of the total patients that experienced a spontaneous episode, the % of patients with a spontaneous rhythm conversion that was successful was determined.
3-month
Wanded Telemetry Issues at Pre-discharge Follow-up
Time Frame: Pre-Discharge visit occurred after implant but prior to 1 month follow-up visit
The Investigators completed a questionnaire based on the performance of the wanded telemetry during device interrogations at pre-discharge follow-up. The number of problems reported were counted from the entire study cohort.
Pre-Discharge visit occurred after implant but prior to 1 month follow-up visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the Daily Median Respiratory Rate Trend in Patients Who Experience a HF-event Compared to Patients Who do Not Experience a HF-event.
Time Frame: Results were captured from implant time window to the first event for patients with HFE, up to an average of 9 months
A comparison of the change in respiratory rate trend over time was made between patients who experienced a protocol-defined HF event (HFE) (Group1: Patients with a HFE) and patients who did not experience a protocol-defined heart failure event (Group 2: Patients without a HFE). Only patients with at least 3 valid daily respiratory rate values (60%) out of each 5-day window were evaluated. The objective was to show that daily median respiratory rate increases more in patients who experience a HFE (Group 1) than in patients who do not experience an HFE (Group 2). A comparison between patients who experience a HFE (Group 1) and patients who do not experience a HFE (Group 2). Two average daily median respiratory rates were done per patient: 60 to 56 days before an index time and 11 to 7 days before the same index time; the difference between these two averaged daily median respiratory rates was done. Index time=day of the first HFE (Group 1) and day of 6-month visit (Group 2).
Results were captured from implant time window to the first event for patients with HFE, up to an average of 9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

December 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

October 22, 2010

First Submitted That Met QC Criteria

October 22, 2010

First Posted (Estimate)

October 25, 2010

Study Record Updates

Last Update Posted (Estimate)

April 25, 2014

Last Update Submitted That Met QC Criteria

April 9, 2014

Last Verified

April 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on INCEPTA ICD or CRT-D

Subscribe